Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival.
Pelizzaro F, Peserico G, D'Elia M, Cazzagon N, Russo FP, Vitale A, Giannini EG, Piccinnu M, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Trevisani F, Farinati F; Italian Liver Cancer (ITA.LI.CA) Study Group.
Pelizzaro F, et al. Among authors: marra f.
Dig Liver Dis. 2022 Jul;54(7):927-936. doi: 10.1016/j.dld.2021.08.025. Epub 2021 Sep 25.
Dig Liver Dis. 2022.
PMID: 34580038